Related references
Note: Only part of the references are listed.Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome
Uh Jin Kim et al.
ANTIVIRAL THERAPY (2016)
Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS
Imran Khalid et al.
RESPIRATORY CARE (2016)
Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
Mohammed Al Ghamdi et al.
BMC INFECTIOUS DISEASES (2016)
Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Nan Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Coronaviruses - drug discovery and therapeutic options
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo
Thomas Luke et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012
Reed F. Johnson et al.
VIROLOGY (2016)
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Jean-Francois Rossingol
JOURNAL OF INFECTION AND PUBLIC HEALTH (2016)
Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
Davide Corti et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2016)
Middle East Respiratory Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013
Asim Malik et al.
EMERGING INFECTIOUS DISEASES (2016)
A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
Jianzhong Cao et al.
ANTIVIRAL RESEARCH (2015)
Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
Kai-Wen Cheng et al.
ANTIVIRAL RESEARCH (2015)
A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
Yan Li et al.
CELL RESEARCH (2015)
IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
Sarah Shalhoub et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
Rudragouda Channappanavar et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Jasper Fuk-Woo Chan et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection
Jincun Zhao et al.
JOURNAL OF VIROLOGY (2015)
Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
Marcel A. Mueller et al.
LANCET INFECTIOUS DISEASES (2015)
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
Tianlei Ying et al.
MICROBES AND INFECTION (2015)
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
Davide Corti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
Kristen E. Pascal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27
Xiaojuan Yu et al.
SCIENTIFIC REPORTS (2015)
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
Yaseen Arabi et al.
SPRINGERPLUS (2015)
Ribavirin and interferon-alpha 2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases
Mohammed Khalid et al.
ANTIVIRAL THERAPY (2015)
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
John Mair-Jenkins et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Antiviral Treatment Guidelines for Middle East Respiratory Syndrome
Yong Pil Chong et al.
INFECTION AND CHEMOTHERAPY (2015)
The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections A Randomized Trial
Ratko Djukanovic et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus Infection
Yaseen M. Arabi et al.
ANNALS OF INTERNAL MEDICINE (2014)
Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia
Mohammad Khalid et al.
ANNALS OF SAUDI MEDICINE (2014)
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
Adriaan H. de Wilde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Julie Dyall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Jean-Francois Rossignol
ANTIVIRAL RESEARCH (2014)
Clinical and Laboratory Findings of the First Imported Case of Middle East Respiratory Syndrome Coronavirus to the United States
Minal Kapoor et al.
CLINICAL INFECTIOUS DISEASES (2014)
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome
David S. Hui et al.
CURRENT OPINION IN PULMONARY MEDICINE (2014)
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
Nikolaos Spanakis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
Jaffar A. Al-Tawfiq et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
Brit J. Hart et al.
JOURNAL OF GENERAL VIROLOGY (2014)
Investigation of Anti-Middle East Respiratory Syndrome Antibodies in Blood Donors and Slaughterhouse Workers in Jeddah and Makkah, Saudi Arabia, Fall 2012
Asad S. Aburizaiza et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis
Jie Zhou et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies
Tianlei Ying et al.
JOURNAL OF VIROLOGY (2014)
A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein
Lanying Du et al.
JOURNAL OF VIROLOGY (2014)
Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
Jason Haffizulla et al.
LANCET INFECTIOUS DISEASES (2014)
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
Ali S. Omrani et al.
LANCET INFECTIOUS DISEASES (2014)
Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Emmanuel Faure et al.
PLOS ONE (2014)
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution
Xian-Chun Tang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein
Liwei Jiang et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry
Wenfei Song et al.
VIROLOGY (2014)
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
Lu Lu et al.
NATURE COMMUNICATIONS (2014)
Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis
Sheng-Yuan Ruan et al.
CRITICAL CARE (2014)
Hyperimmune IV Immunoglobulin Treatment A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza A(H1N1) Infection
Ivan F. N. Hung et al.
CHEST (2013)
Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment
Susanna K. P. Lau et al.
JOURNAL OF GENERAL VIROLOGY (2013)
MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment
Adriaan H. de Wilde et al.
JOURNAL OF GENERAL VIROLOGY (2013)
Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
Kwok-Hung Chan et al.
JOURNAL OF INFECTION (2013)
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Jasper F. W. Chan et al.
JOURNAL OF INFECTION (2013)
Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2
Kazuya Shirato et al.
JOURNAL OF VIROLOGY (2013)
Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody
Kei Ohnuma et al.
JOURNAL OF VIROLOGY (2013)
The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies
Huihui Mou et al.
JOURNAL OF VIROLOGY (2013)
Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures
Renee W. Y. Chan et al.
JOURNAL OF VIROLOGY (2013)
Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus
Florian Zielecki et al.
JOURNAL OF VIROLOGY (2013)
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj et al.
NATURE (2013)
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
Darryl Falzarano et al.
NATURE MEDICINE (2013)
A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
Lanying Du et al.
PLOS ONE (2013)
In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection
Isabella Eckerle et al.
VIROLOGY JOURNAL (2013)
Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus
Laurence Josset et al.
MBIO (2013)
Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential
Eveline Kindler et al.
MBIO (2013)
Inhibition of novel β coronavirus replication by a combination of interferon- α2b and ribavirin
Darryl Falzarano et al.
SCIENTIFIC REPORTS (2013)
Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia
Stefanie Gierer et al.
EMERGING INFECTIOUS DISEASES (2013)
Primary Severe Acute Respiratory Syndrome Coronavirus Infection Limits Replication but Not Lung Inflammation upon Homologous Rechallenge
Candice Clay et al.
JOURNAL OF VIROLOGY (2012)
Corticosteroid Treatment in Critically Ill Patients with Pandemic Influenza A/H1N1 2009 Infection Analytic Strategy Using Propensity Scores
Sung-Han Kim et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection
Ivan F. N. Hung et al.
CLINICAL INFECTIOUS DISEASES (2011)
Cyclosporin A inhibits the replication of diverse coronaviruses
Adriaan H. de Wilde et al.
JOURNAL OF GENERAL VIROLOGY (2011)
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial
Nicholas I. Paton et al.
LANCET INFECTIOUS DISEASES (2011)
Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
Elena Lopez Aspiroz et al.
THERAPEUTIC DRUG MONITORING (2011)
A Single Asparagine-Linked Glycosylation Site of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms
Yanchen Zhou et al.
JOURNAL OF VIROLOGY (2010)
Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome
Xinsheng Zhang et al.
JOURNAL OF VIROLOGY (2008)
Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro
Feng Yang et al.
JOURNAL OF VIROLOGY (2008)
Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon
Luisa Cervantes-Barragan et al.
BLOOD (2007)
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
Dale L. Barnard et al.
ANTIVIRAL RESEARCH (2006)
In vitro inhibition of human influenza A virus replication by chloroquine
Eng Eong Ooi et al.
VIROLOGY JOURNAL (2006)
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro
J Paeshuyse et al.
HEPATOLOGY (2006)
SARS: Systematic review of treatment effects
Lauren J. Stockman et al.
PLOS MEDICINE (2006)
Coronaviruses and their therapy
Bart L. Haagmans et al.
ANTIVIRAL RESEARCH (2006)
Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital
KM Yeh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase
K Watashi et al.
MOLECULAR CELL (2005)
Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection
WKE Ip et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids
JF Griffith et al.
RADIOLOGY (2005)
Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
B Morgenstern et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
Use of convalescent plasma therapy in SARS patients in Hong Kong
Y Cheng et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs
ELC Tan et al.
EMERGING INFECTIOUS DISEASES (2004)
Severe acute respiratory syndrome related coronavirus is inhibited by interferon-α
U Ströher et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids
BM Jones et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
BL Haagmans et al.
NATURE MEDICINE (2004)
Short-term outcome of critically ill patients with severe acute respiratory syndrome
CD Gomersall et al.
INTENSIVE CARE MEDICINE (2004)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
Interferon-β 1a and SARS coronavirus replication
LE Hensley et al.
EMERGING INFECTIOUS DISEASES (2004)
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
F Chen et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Small molecules targeting severe acute respiratory syndrome human coronavirus
CY Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
YOY Soo et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
N Lee et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Avascular necrosis of bone in severe acute respiratory syndrome
N Hong et al.
CLINICAL RADIOLOGY (2004)
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)
B Sainz et al.
VIROLOGY (2004)
Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets
H Weingartl et al.
JOURNAL OF VIROLOGY (2004)
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
E Keyaerts et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients
JT Wang et al.
EMERGING INFECTIOUS DISEASES (2004)
Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak
JJY Sung et al.
THORAX (2004)
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome - A preliminary study
MR Loutfy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome
JC Ho et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Temporal patterns of hepatic dysfunction and disease severity in patients with SARS
WM Wong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
SR Knowles et al.
CLINICAL INFECTIOUS DISEASES (2003)
Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
Z Zhao et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2003)
Fatal aspergillosis in a patient with SARS who was treated with corticosteroids
HJ Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Treatment of SARS with human interferons
J Cinatl et al.
LANCET (2003)
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
J Cinatl et al.
LANCET (2003)
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
CM Booth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
JSM Peiris et al.
LANCET (2003)
Coronavirus as a possible cause of severe acute respiratory syndrome
JSM Peiris et al.
LANCET (2003)
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
S Crotty et al.
NATURE MEDICINE (2000)
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
W Markland et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
